Roche Holding/€ROP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Roche Holding
- Ticker
- €ROP
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 103,249
- Headquarters
- Basel, Switzerland
- Website
- www.roche.com
Roche Holding Metrics
BasicAdvanced
€349B
26.12
€16.67
0.33
-
Price and volume
Market cap
€349B
Beta
0.33
52-week high
€425.50
52-week low
€323.19
Average daily volume
1.4K
Financial strength
Current ratio
1.228
Quick ratio
0.8
Long term debt to equity
0.728
Total debt to equity
0.908
Dividend payout ratio (TTM)
63.22%
Interest coverage (TTM)
18.24%
Profitability
EBITDA (TTM)
26,052.223
Gross margin (TTM)
74.17%
Net profit margin (TTM)
19.60%
Operating margin (TTM)
33.12%
Effective tax rate (TTM)
18.74%
Revenue per employee (TTM)
€663,150
Management effectiveness
Return on assets (TTM)
13.51%
Return on equity (TTM)
38.11%
Valuation
Price to earnings (TTM)
26.12
Price to revenue (TTM)
5.064
Price to book
9.82
Price to tangible book (TTM)
57.26
Price to free cash flow (TTM)
22.948
Free cash flow yield (TTM)
4.36%
Free cash flow per share (TTM)
18.974
Growth
Revenue change (TTM)
-0.83%
Earnings per share change (TTM)
30.57%
3-year revenue growth (CAGR)
0.23%
10-year revenue growth (CAGR)
2.01%
3-year earnings per share growth (CAGR)
3.87%
10-year earnings per share growth (CAGR)
3.82%
3-year dividend per share growth (CAGR)
1.04%
10-year dividend per share growth (CAGR)
1.92%
Bulls say / Bears say
First-half group sales rose 6% at constant exchange rates and core operating profit rose 10%, while Roche kept its 2026 targets for mid-single-digit sales growth and high-single-digit core EPS growth. This gives the business solid current momentum, not just a reliance on future launches. (Roche)
Giredestrant improved progression-free survival in a Phase III breast-cancer trial, and the FDA is due to decide on two applications by 30 November and 18 December 2026. The results create near-term potential for a new growth product, although approval and uptake are not yet assured. (Roche)
The FDA cleared Roche’s Elecsys pTau217 blood test to help assess Alzheimer’s-related amyloid pathology, giving its diagnostics business a new product in a major area of unmet need. Roche says it is the first single-biomarker test cleared to support both rule-in and rule-out assessment using the same cut-offs. (Roche)
The stronger Swiss franc dragged first-half sales down 2% in reported francs, despite 6% growth at constant exchange rates. That gap shows currency movements can obscure underlying progress in Roche’s reported results. (Reuters)
Biosimilar competition continues to erode established medicines: sales of Roche’s products with expired patents fell 8% at constant exchange rates in the first half. This leaves the company needing newer products to offset declining legacy revenue. (Roche)
China’s healthcare pricing reforms are weighing on Diagnostics: Roche reported a 15% constant-currency decline in its China sales in the first half. The pressure limits growth in a division that rose just 3% overall at constant exchange rates. (Roche)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2026.
Roche Holding Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
Funds containing Roche Holding
AllUSDEURGBP
Fund name | Fund size | €ROP weighting |
|---|---|---|
SPDR MSCI World Health Care£HEAW | $708M | 3.81% |
SPDR MSCI World Health Care$WHEA | $708M | 3.81% |
Xtrackers MSCI World Health Care$XDWH | $4.1B | 3.80% |
Xtrackers MSCI World Health Care£XWHS | $4.1B | 3.80% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 2.75% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.